Carrillo-Torres O, Camacho-Vacherón V

Language: Spanish
References: 5
Page: 217-220
PDF size: 136.86 Kb.

ABSTRACT

The therapeutic targets for control in postoperative pain are increasingly well known. Among them are those involved in voltage, ion, transporter, G-protein, molecular recognition, peptide, neutrophic, enzymatic, cytokinic, cellular, epigenetic and genetic channels. We can also divide the therapeutic targets into three large groups depending on their interference; those that act in acute pain, those that will break into the chronic pain generation and those focused on hyperalgesia. Of course, almost everyone is involved in the mechanism of the three pain groups although they infer more concisely in one of them.

REFERENCES

1. Guo R, Zhao Y, Zhang M, Wang Y, Shi R, Liu Y, et al. Downregulation of stargazin inhibits the enhanced surface delivery of α-amino-3-hydroxy-5- methyl-4-isoxazole propionate (AMPA) receptor GluR1 subunit in rat dorsal horn and ameliorates postoperative pain. Anesthesiolgy. 2014;121:609-619.

2. Lee CH, Chen CC. Roles of ASICs in nociception and proprioception. Adv Exp Med Biol. 2018;1099:37-47.

3. Kapur BM, Lala PK, Shaw JLV. Pharmacogenetics of chronic pain management. Clin Biochem. 2014;47:13-14.

4. Bennett DL, Woods CG. Painful and painless channelopathies. Lancet Neurol. 2014;13:587-599.

5. Wieskopf JS, Mathur J, Limapichat W, Post MR, Al-Qazzaz M, Sorge RE, et al. The nicotinic a6 subunit gene determines variability in chronic pain sensitivity via cross-inhibition of P2X2/3 receptors. Pain. 2015;287:1-14.